Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ATRC declined for three days, in 255 of 308 cases, the price declined further within the following month. The odds of a continued downward trend are 83%.
The 10-day RSI Indicator for ATRC moved out of overbought territory on September 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for ATRC turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ATRC as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +1.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATRC advanced for three days, in 215 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ATRC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 156 of 222 cases where ATRC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.680) is normal, around the industry mean (4.952). ATRC's P/E Ratio (262.136) is considerably higher than the industry average of (36.644). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.869) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The RSI Indicator for CERS moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 22 of the 28 cases the stock moved higher. This puts the odds of a move higher at 79%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CERS as a result. In 78 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for CERS just turned positive on October 20, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in 32 of 44 cases over the following month. The odds of a continued upward trend are 73%.
Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 170 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CERS broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CERS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.878) is normal, around the industry mean (2.923). P/E Ratio (-79.667) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ATRC | CERS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 83 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 88 | 94 | |
PRICE GROWTH RATING 1..100 | 35 | 57 | |
P/E GROWTH RATING 1..100 | 7 | 19 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CERS's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for ATRC (94). This means that CERS’s stock grew significantly faster than ATRC’s over the last 12 months.
CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ATRC (100). This means that CERS’s stock grew similarly to ATRC’s over the last 12 months.
ATRC's SMR Rating (88) in the Medical Specialties industry is in the same range as CERS (94). This means that ATRC’s stock grew similarly to CERS’s over the last 12 months.
ATRC's Price Growth Rating (35) in the Medical Specialties industry is in the same range as CERS (57). This means that ATRC’s stock grew similarly to CERS’s over the last 12 months.
ATRC's P/E Growth Rating (7) in the Medical Specialties industry is in the same range as CERS (19). This means that ATRC’s stock grew similarly to CERS’s over the last 12 months.
| ATRC | CERS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 82% |
| Advances ODDS (%) | 8 days ago 71% | 2 days ago 75% |
| Declines ODDS (%) | 4 days ago 83% | 15 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 85% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATRC’s FA Score shows that 1 FA rating(s) are green while CERS’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATRC’s TA Score shows that 4 TA indicator(s) are bullish while CERS’s TA Score has 4 bullish TA indicator(s).
ATRC (@Pharmaceuticals: Other) experienced а +0.65% price change this week, while CERS (@Medical/Nursing Services) price change was +6.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.63%. For the same industry, the average monthly price growth was -3.82%, and the average quarterly price growth was +8.73%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
ATRC is expected to report earnings on Nov 03, 2026.
CERS is expected to report earnings on Nov 02, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ATRC has been loosely correlated with CERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRC jumps, then CERS could also see price increases.
| Ticker / NAME | Correlation To ATRC | 1D Price Change % | ||
|---|---|---|---|---|
| ATRC | 100% | N/A | ||
| CERS - ATRC | 42% Loosely correlated | +3.46% | ||
| SIBN - ATRC | 41% Loosely correlated | +1.36% | ||
| IRMD - ATRC | 38% Loosely correlated | -0.49% | ||
| TMCI - ATRC | 37% Loosely correlated | +1.72% | ||
| MXCT - ATRC | 37% Loosely correlated | +2.80% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NFXS | 23.07 | 1.14 | +5.21% |
| Direxion Daily NFLX Bear 1X ETF (NFXS) | |||
| WBIL | 40.36 | 0.71 | +1.80% |
| WBI BullBear Quality 3000 ETF (WBIL) | |||
| ERH | 10.51 | 0.08 | +0.77% |
| Allspring Utilities and High Income Fund | |||
| VTP | 73.21 | 0.03 | +0.04% |
| Vanguard Total Inflation-Protected Securities ETF (VTP) | |||
| VTC | 73.38 | -0.04 | -0.05% |
| Vanguard Total Corporate Bond ETF (VTC) | |||